Evidence map›Paper›PMID 27073619›Full record

ArticleBiomedical reports2016

Moieties in antidiabetic drugs as a target of insulin receptors in association with common neurological disorders.

David Calderón Guzmán, Hugo Juárez Olguín, Ernestina Hernández García, Maribel Ortiz Herrera, Norma Osnaya Brizuela

Open access · bronzeAbstract read
In one paragraph

Article in Biomedical reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

David Calderón GuzmánLaboratory of Neurochemistry, National Institute of Pediatrics, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, CP 04530, Mexico.
Hugo Juárez OlguínLaboratory of Pharmacology, National Institute of Pediatrics, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, CP 04530, Mexico.
Ernestina Hernández GarcíaLaboratory of Pharmacology, National Institute of Pediatrics, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, CP 04530, Mexico.
Maribel Ortiz HerreraLaboratory of Experimental Bacteriology, National Institute of Pediatrics, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, CP 04530, Mexico.
Norma Osnaya BrizuelaLaboratory of Neurochemistry, National Institute of Pediatrics, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, CP 04530, Mexico.
Universidad Nacional Autónoma de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin is a peptide that can be harmful with regards to neuroplasticity, neuroprotection and neuromodulation. Furthermore, the role of insulin highlights its relevance in the progress of diverse clinical disorders as well as in the mechanisms associated with certain pathogenesis and their evolution towards diabetes, obesity and neurodegenerative diseases. The precise molecular mechanisms by which these diseases are induced remain to be elucidated. The benefits in knowing/discovering these mechanisms in animal models and humans cannot be undermined. An in depth understanding of the principal risk factors leading to obesity and their management is vital in the implementation of early-life strategies of intervention and prevention, with a view to avoid adverse late-life outcomes. Therefore, the aim of the present study was to review their possible association with antidiabetic drugs.

Indexed as

antidiabetic drugscentral nervous systeminsulinneurodegenerative disordersobesity

Identifiers

PMID27073619
PMCPMC4812541
OpenAlexW2287957375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.